And soon, there will be three.
Johnson & Johnson recently submitted its COVID-19 vaccine to the U.S. Food and Drug Administration for emergency use authorization. That step could eventually make it the third vaccine to be approved in the battle against the novel coronavirus pandemic, joining vaccines made by Moderna and Pfizer with its German partner BioNTech.
It might be March before the Johnson & Johnson’s entry into the race to vaccinate the nation and world wins FDA approval.
Cindy A. Prins, Ph.D., M.P.H., a University of Florida Health infectious disease epidemiologist who is an associate professor in the UF College of Public Health and Health Professions and the UF College of Medicine, explains key points about this newest player on the COVID-19 vaccination front.
Experimental Therapy Promising for Severe Muscular Dystrophy newsmax.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from newsmax.com Daily Mail and Mail on Sunday newspapers.
Study: Children nearly 60% more likely than older adults to spread COVID-19
Jill Pease, University of Florida
Updated:
Tags:
The study was based on contact tracing data from thousands of households in Wuhan, China.
The findings, which appear in Lancet Infectious Diseases, emphasize the need to conduct COVID-19 vaccine safety and efficacy studies in children, said Dr. Yang Yang, one of the study’s senior authors and an associate professor of biostatistics in the UF College of Public Health and Health Professions and the UF College of Medicine, part of UF Health.
Ad
“We also need to take into account the potential high infectivity of children when we plan school re-openings and what prevention measures we need to take during active school sessions,” said Yang, a member of UF’s Emerging Pathogens Institute.